Nevertheless, our findings make PARP1 an attractive target for CD therapy and provide an impetus for testing the efficacy of a variety of PARP1 inhibitors in controlling chronic inflammatory infiltrate and cardiac fibrosis, the two hallmarks of CD severity, in multiple mammalian hosts. Here, PARP1 is linked to Cowden disease.